Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,794 total articles
Arista Networks sits in the critical “picks and shovels” layer of AI buildouts: high-speed switching, routing, and software that keeps data centers from choking on bandwidth. The stock is extended but technically strong, with bullish momentum signals and a clear level to define risk. This trade idea leans long, targeting a push back toward the prio…
Fortinet has the profile of a “boring” cybersecurity compounder that tends to look most interesting when the tape is choppy and the narrative turns temporarily negative. The stock is down materially from its $114.82 52-week high and is now trading around $81.57, even as the company continues to generate meaningful free cash flow and maintains stron…
Credo Technology is a pure-play on high-speed connectivity inside AI data centers. After a sharp drawdown from its 52-week high, CRDO is now trading with a depressed RSI and below key moving averages, setting up a defined-risk dip-buy trade. The bull case leans on real operating momentum (including triple-digit revenue growth cited in recent covera…
Lemonade has been trading like a momentum stock, but the underlying story the market is buying is simpler: AI-driven distribution plus better loss performance, inching the model toward profitability. With shares near $90 after a sharp run to $99.90, LMND offers a defined-risk long setup using the rising 10-day/20-day trend as a line in the sand. Th…
REGENXBIO (RGNX) is a clinical-stage gene therapy name with a clear event-window setup: a key FDA decision on its Hunter syndrome program is approaching, and the stock is coiling below near-term technical levels. With a ~$701M market cap, negative EPS (-$3.51), and meaningful short interest (about 5.0M shares; ~7.3 days to cover), price action can …
Energy Transfer is quietly tightening its operating narrative around long-life, contracted natural gas capacity, and the market is starting to pay attention. With ET back near $18, a 52-week range of $14.60-$21.16, and bullish technical momentum, the trade setup is attractive if you respect the overbought signals. This is a mid-term (45 trading day…
Intel has sprinted off its 2025 lows and is now pulling back from a fresh 52-week high near $54.60. The tape looks like a classic digestion phase: RSI is neutral (~47.8), price is sitting near the 20-day average, and MACD is still barely positive. My trade idea is to go long on this reset, looking for a move back toward the mid-to-upper $50s as 202…
Nebius (NBIS) is acting like a classic AI infrastructure momentum name: headline-driven volatility on top of a simpler underlying engine - demand for GPU capacity. With shares back near a key support zone around the mid-$90s and short interest elevated, the risk-reward favors a defined long trade as long as $91 support holds. This is not a ‘sleep w…
Allstate is trading like underwriting is still fully at the mercy of the cycle. But the profitability profile implied by a 30% ROE and a single-digit P/E suggests a structurally improved earnings engine. With the stock sitting below key moving averages and momentum still bearish, this is a mid-term long idea that looks like it’s offering entry rath…
Pfizer is trading around $25.88 with improving momentum and a 6.65% dividend yield. Even as the market debates big-picture healthcare policy shifts, PFE’s valuation looks compressed versus its cash generation profile and the stock is building a base just under the 52-week high. This trade idea targets a measured breakout with defined risk, leaning …
Spotify has pulled back sharply from its 52-week highs and is now sitting near short-term moving averages with an oversold RSI around 35. The tape still shows bearish momentum, but the dip is starting to look more like exhaustion than the start of a fresh breakdown. This trade idea is a defined-risk long that leans on mean reversion back toward the…
Alphabet has climbed back near its highs with a ~$4.02T market cap and a ~$335 share price, but the valuation is getting harder to justify if free cash flow doesn’t re-accelerate. At ~32x earnings and a rich ~55x free cash flow multiple, the market is paying up for an AI-driven upside scenario at the same time momentum is rolling over (bearish MACD…
Strattec Security (STRT) is an overlooked auto supplier trading at modest earnings and low sales multiples despite strong free cash flow generation, low leverage, and improving operational execution. With the stock consolidating below recent highs and valuation still reasonable, the setup favors a defined-risk long trade aimed at a retest of the 52…
Kroger has quietly tightened its narrative around core grocery, leaned into personalization through Google Cloud’s Gemini CX rollout, and backed shareholder returns with a new $2 billion repurchase authorization. With shares near $63.70, improving momentum signals, and a defensive demand profile, KR offers a pragmatic mid-term long setup: defined d…
ClearPoint Neuro sold off hard into $14 despite improving momentum signals and steady liquidity metrics. With the stock sitting near its 50-day average, short interest elevated, and the business positioned around MRI-guided minimally invasive neurosurgery platforms, the risk-reward favors a defined mid-term rebound trade back toward the mid-teens t…
Dyne Therapeutics sits at an interesting intersection for biotech traders: a beaten-down-to-basing chart near $18, meaningful short interest, and a 2026 narrative tied to progress in genetically driven muscle diseases. With liquidity that looks more like a well-funded developer than a fragile microcap, the risk can be framed with a clean stop while…
OPKO Health (OPK) sits in a weird place the market tends to misprice: a sub-$1.1B health services and biopharma hybrid with credible assets, real operating infrastructure, and a long history that has trained investors to shrug. At ~$1.30, the stock is priced like the future is mostly disappointment. But the setup says the opposite is plausible - va…
FLGT has rebounded enough that the stock no longer screams deep value, but valuation is still reasonable for a company with no debt, strong liquidity, and a chart that’s stabilizing. I like a defined-risk long trade into the $30-$31 area, with a tight stop under recent support.
Upstart (UPST) has been treated like a simple consumer-credit grenade, but the market may be overlooking the real asset: a scalable AI underwriting platform that can reaccelerate as risk appetite returns. With the stock near $46, mixed momentum indicators, and short interest still elevated, the setup looks less like a momentum chase and more like a…
Horizon Bancorp trades like a small regional bank the market doesn’t quite trust, but the tape is stabilizing, momentum is improving, and the valuation already prices in a lot of bad news. With margin pressure likely closer to trough than peak, HBNC offers an actionable mid-term long setup with defined risk near support and upside back toward the r…
Dave’s stock is off its highs, momentum is still bearish, and RSI is depressed - but the business metrics underneath look legitimately strong for a fintech this size. With a $2.48B market cap, profitable economics (P/E ~17-18), and meaningful free cash flow, DAVE offers a tactical long setup that targets a rebound back toward key moving averages wh…
Ovid Therapeutics is trying to earn back credibility after a brutal 2024 drawdown, but the setup into early 2026 is cleaner than most: liquid balance-sheet ratios, rising short interest that can fuel upside, and bullish near-term technical momentum. With the stock at $1.74 and still below the $2.01 52-week high, the trade is a mid-term breakout att…
Rigel (RIGL) is trading around $37 after a sharp pullback from its $52.24 52-week high, with momentum still bearish but valuation metrics that look unusually compressed for a profitable biotech. With a ~$671M market cap, ~5.9x P/E, ~2.38x sales, and ~$68.1M in free cash flow, the setup is a fundamentals-backed rebound trade if price can reclaim key…
Angi’s stock is acting like a business that has finally gotten its basics under control: liquidity is solid, valuation is modest, and the chart is starting to cooperate. With elevated short interest and a market cap that implies little confidence in a demand rebound, ANGI sets up as a mid-term trade where “less bad” can be enough. The plan: buy str…
Newmont has rallied hard with gold, yet the stock still screens like a business the market doesn’t fully trust. With gold printing new highs, Newmont’s scale, liquidity, and cash generation matter more than ever. The setup is bullish but extended near fresh 52-week highs, so the trade plan focuses on a controlled entry, clear invalidation, and a re…
